Xie Ying, Murray-Stewart Tracy, Wang Yazhe, Yu Fei, Li Jing, Marton Laurence J, Casero Robert A, Oupický David
Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, United States.
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, United States.
J Control Release. 2017 Jan 28;246:110-119. doi: 10.1016/j.jconrel.2016.12.017. Epub 2016 Dec 23.
Combination of anticancer drugs with therapeutic microRNA (miRNA) has emerged as a promising anticancer strategy. However, the promise is hampered by a lack of desirable delivery systems. We report on the development of self-immolative nanoparticles capable of simultaneously delivering miR-34a mimic and targeting dysregulated polyamine metabolism in cancer. The nanoparticles were prepared from a biodegradable polycationic prodrug, named DSS-BEN, which was synthesized from a polyamine analog N,N-bisethylnorspermine (BENSpm). The nanoparticles were selectively disassembled in the cytoplasm where they released miRNA. Glutathione (GSH)-induced degradation of self-immolative linkers released BENSpm from the DSS-BEN polymers. MiR-34a mimic was effectively delivered to cancer cells as evidenced by upregulation of intracellular miR-34a and downregulation of Bcl-2 as one of the downstream targets of miR-34a. Intracellular BENSpm generated from the degraded nanoparticles induced the expression of rate-limiting enzymes in polyamine catabolism (SMOX, SSAT) and depleted cellular natural polyamines. Simultaneous regulation of polyamine metabolism and miR-34a expression by DSS-BEN/miR-34a not only enhanced cancer cell killing in cultured human colon cancer cells, but also improved antitumor activity in vivo. The reported findings validate the self-immolative nanoparticles as delivery vectors of therapeutic miRNA capable of simultaneously targeting dysregulated polyamine metabolism in cancer, thereby providing an elegant and efficient approach to combination nanomedicines.
抗癌药物与治疗性微小RNA(miRNA)的联合使用已成为一种有前景的抗癌策略。然而,这一前景因缺乏理想的递送系统而受到阻碍。我们报道了一种自毁型纳米颗粒的研发,该纳米颗粒能够同时递送miR-34a模拟物并靶向癌症中失调的多胺代谢。这些纳米颗粒由一种可生物降解的聚阳离子前药制备而成,名为DSS-BEN,它是由多胺类似物N,N-双乙基去甲精胺(BENSpm)合成的。纳米颗粒在细胞质中被选择性拆解,在那里释放出miRNA。谷胱甘肽(GSH)诱导的自毁型连接子降解使BENSpm从DSS-BEN聚合物中释放出来。miR-34a模拟物被有效地递送至癌细胞,细胞内miR-34a的上调以及作为miR-34a下游靶点之一的Bcl-2的下调证明了这一点。由降解的纳米颗粒产生的细胞内BENSpm诱导了多胺分解代谢中限速酶(SMOX、SSAT)的表达,并耗尽了细胞内的天然多胺。DSS-BEN/miR-34a对多胺代谢和miR-34a表达的同时调节不仅增强了对培养的人结肠癌细胞的杀伤作用,还提高了体内抗肿瘤活性。报道的研究结果证实了自毁型纳米颗粒作为治疗性miRNA的递送载体,能够同时靶向癌症中失调的多胺代谢,从而为联合纳米药物提供了一种优雅而有效的方法。